GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tocagen Inc (NAS:TOCA) » Definitions » Notes Receivable

Tocagen (Tocagen) Notes Receivable : $0.00 Mil (As of Mar. 2020)


View and export this data going back to 2017. Start your Free Trial

What is Tocagen Notes Receivable?

Tocagen's Notes Receivable for the quarter that ended in Mar. 2020 was $0.00 Mil.


Tocagen Notes Receivable Historical Data

The historical data trend for Tocagen's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tocagen Notes Receivable Chart

Tocagen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19
Notes Receivable
- - - - -

Tocagen Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Tocagen Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Tocagen Notes Receivable Related Terms

Thank you for viewing the detailed overview of Tocagen's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Tocagen (Tocagen) Business Description

Traded in Other Exchanges
N/A
Address
4242 Campus Point Court, Suite 500, San Diego, CA, USA, 92121
Tocagen Inc is a clinical-stage, cancer-selective gene therapy company. It is focused on developing product candidates designed to activate a patient's immune system against their own cancer from within. The company's cancer-selective gene therapy platform is built on retroviral replicating vectors, or RRVs, which are designed to selectively deliver therapeutic genes into the DNA of cancer cells. Tocagen is developing product candidate, Toca 511 and Toca FC, for the treatment of recurrent high grade glioma, or HGG, a brain cancer with limited treatment options, low survival rates and, therefore, a significant unmet medical need. Geographically, the activities are carried out through United States.